Pharmacological and clinical profile of exemestane (Aromasin®), a novel irreversible aromatase inhibitor

Folia Pharmacologica Japonica

Volumn 122, Issue 4, 2003, Pages 345-354

  Tahara, Makoto ^a   Nomura, Shunji ^a   Hashimoto, Munehiro ^a  

^a PFIZER INC   (United States)

Author keywords

Aromasin; Aromatase inhibitor; Estrogen; Exemestane; Postmenopausal breast cancer

Indexed keywords

ALDOSTERONE; AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTENEDIONE; AROMATASE; AROMATASE INHIBITOR; ATAMESTANE; CHOLESTEROL; DIMETHYLBENZ[A]ANTHRACENE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTRONE; EXEMESTANE; FADROZOLE; FORMESTANE; GLUCOCORTICOID RECEPTOR; HYDROXYPROGESTERONE; LETROZOLE; MINERALOCORTICOID RECEPTOR; PREGNENOLONE; PROGESTERONE; PROGESTERONE RECEPTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SERIC GONADOTROPIN; TESTOSTERONE; TESTOSTERONE PROPIONATE; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER MODEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVALENT BOND; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME SUBSTRATE; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; ESTROGEN SYNTHESIS; HORMONE ACTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OUTCOMES RESEARCH; OVARIECTOMY; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PREMENOPAUSE; RAT; REVIEW;

ANDROSTADIENES; ANIMALS; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; CLINICAL TRIALS, PHASE II; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; RATS;

EID: 0142023916     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.122.345     Document Type: Review

References (18)

1. Brueggemeier RW. Overview of the pharmacology of the aromatase inactivator exemestane. Breast Cancer Res Treat. 2002;74:177-185.
2. Di Salle E, Ornati G, Giudici D, Lassus M, Evans TRJ, Coombes RC. Exemestane (FCE 24304), a new steroidal aromatase inhibitor. J Steroid Biochem Mol Biol. 1992;43:137-143.
3. Di Salle E, Briatico G, Giudici D, et al. Novel aromatase and 5α-reductase inhibitors. J Steroid Biochem Mol Biol. 1994;49:289-294.
4. Miller WR, Dixon JM. Antiaromatase agents: preclinical data and neoadjuvant therapy. Clin Breast Cancer. 2000;1:S9-S14.
5. Chen S, Zhou D, Okubo T, Kao YC, Yang C. Breast tumor aromatase: functional role and transcriptional regulation. Endocr Relat Cancer. 1999;6:149-156.
6. Harada N, Honda SI, Hatano O. Aromatase inhibitors and enzyme stability. Endocr Relat Cancer. 1999;6:211-218.
7. Miller WR. Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treatment Reviews. 1989;16:89-93.
8. Lombardi P. Exemestane, a new steroidal aromatase inhibitor of clinical relevance. Biochim Biophys Acta. 2002;1587:326-337.
9. Giudici D, Ornati G, Briatico G, Buzzetti F, Lombardi P, Di Salle E. 6-Methylenandrosta-1,4-diene-3, 17-dione (FCE 24304): a new irreversible aromatase inhibitor. J Steroid Biochem. 1988;30: 391-394.
10. Di Salle E, Giudici D, Briatico G, Ornati G. Novel irreversible aromatase inhibitors. Ann NY Acad Sci. 1990;595:357-367.
11. Zaccheo T, Giudici D, Lombardi P, Di Salle E. A new irreversible aromatase inhibitor, 6-methylenandrosta-1,4-diene-3,17-dione (FCE 24304): antitumor activity and endocrine effects in rats with DMBA-induced mammary tumors. Cancer Chemother Pharmacol. 1989;23:47-50.
12. Zaccheo T, Di Salle E. Effect of the irreversible aromatase inhibitor FCE 24304 on DMBA-induced mammary tumors in ovariectomized rats treated with testosterone. Cancer Chemother Pharmacol. 1989;25:95-98.
13. Miura S, Tominaga T, Koyama H, Nomura Y, Tsuboi M. Phase I single-dose administration study of exemestane in postmenopausal women. Jpn J Cancer Chemother. 2002;29:1179-1187.
14. Miura S, Tominaga T, Koyama H, Nomura Y, Tsuboi M. Phase I multiple-dose administration study of exemestane in postmenopausal women. Jpn J Cancer Chemother. 2002;29:1189-1197.
15. Tabei T, Ogita M, Hirata K, et al. Early phase II dose-finding study of exemestane in postmenopausal patients with advanced/recurrent breast cancer. Jpn J Cancer Chemother. 2002;29:1199-1209.
16. Watanabe T, Sano M, Toi M, et al. Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents. Jpn J Cancer Chemother. 2002;29:1211-1221.
17. Dirix L et al. Efficacy of and tolerance to exemestane (E) versus tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): A European organization for the research and treatment of cancer (EORTC Breast Group) II trial with Pharmacia and Upjohn. Proc Ann Meet Am Soc Clin Oncol. 2001; (abstr 114)
18. Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized phase II multi-centre study of exemestane versus tamoxifen as first line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol. In press.